Can lacosamide reverse human osteoarthritis by blocking CRMP2-driven cartilage degradation?

A mechanistic reading asks whether lacosamide’s effects could instead involve CRMP2. Studies report that the inactive (S)-lacosamide stereoisomer affects CRMP2 phosphorylation and CaV2.2 activity in sensory neurons, while a review highlights contradictory evidence about direct CRMP2 binding. This supports a possible pain-related CRMP2 pathway, but the supplied evidence does not connect it causally to cartilage degradation in osteoarthritis.

• (S)-lacosamide, rather than the clinically used (R)-lacosamide, was reported to inhibit CRMP2 phosphorylation and reduce calcium currents in sensory neurons.
• CRMP2-related lacosamide research links the protein to neuronal excitability, CaV2.2 regulation, and pain behaviors—not directly to cartilage breakdown.
• A review describes contradictory reports concerning lacosamide’s binding to CRMP2 and its direct effects on CRMP2 function.
• The proposed CRMP2 explanation therefore remains mechanistically distinct from, and unproven in, the osteoarthritis cartilage findings.

Featured sourceCollagen II hydrogel-mediated sustained delivery of lacosamide attenuates cartilage degeneration and pain in osteoarthritis - PubMedpubmed.ncbi.nlm.nih.gov4 sourcesView sources